133 related articles for article (PubMed ID: 10428197)
1. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor.
Wan XS; Meyskens FL; Armstrong WB; Taylor TH; Kennedy AR
Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):601-8. PubMed ID: 10428197
[TBL] [Abstract][Full Text] [Related]
2. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
Armstrong WB; Kennedy AR; Wan XS; Taylor TH; Nguyen QA; Jensen J; Thompson W; Lagerberg W; Meyskens FL
Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
[TBL] [Abstract][Full Text] [Related]
3. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
Wan XS; Serota DG; Ware JH; Crowell JA; Kennedy AR
Nutr Cancer; 2002; 43(2):167-73. PubMed ID: 12588697
[TBL] [Abstract][Full Text] [Related]
4. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
Armstrong WB; Wan XS; Kennedy AR; Taylor TH; Meyskens FL
Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
[TBL] [Abstract][Full Text] [Related]
5. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
Armstrong WB; Kennedy AR; Wan XS; Atiba J; McLaren CE; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
Malkowicz SB; Liu SP; Broderick GA; Wein AJ; Kennedy AR; Levin RM
Neurourol Urodyn; 2003; 22(1):54-7. PubMed ID: 12478602
[TBL] [Abstract][Full Text] [Related]
7. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
Kennedy AR; Szuhaj BF; Newberne PM; Billings PC
Nutr Cancer; 1993; 19(3):281-302. PubMed ID: 8346077
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of oral carcinogenesis by a protease inhibitor.
Messadi DV; Billings P; Shklar G; Kennedy AR
J Natl Cancer Inst; 1986 Mar; 76(3):447-52. PubMed ID: 3081747
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
Zhang L; Wan XS; Donahue JJ; Ware JH; Kennedy AR
Nutr Cancer; 1999; 33(2):165-73. PubMed ID: 10368812
[TBL] [Abstract][Full Text] [Related]
10. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer.
Meyskens FL
Ann N Y Acad Sci; 2001 Dec; 952():116-23. PubMed ID: 11795430
[TBL] [Abstract][Full Text] [Related]
11. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
[TBL] [Abstract][Full Text] [Related]
12. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
Chen YW; Huang SC; Lin-Shiau SY; Lin JK
Carcinogenesis; 2005 Jul; 26(7):1296-306. PubMed ID: 15746161
[TBL] [Abstract][Full Text] [Related]
13. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
Kennedy AR; Billings PC; Wan XS; Newberne PM
Nutr Cancer; 2002; 43(2):174-86. PubMed ID: 12588698
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum.
Kennedy CW; Donahue JJ; Wan XS
Nutr Cancer; 1996; 26(2):209-17. PubMed ID: 8875558
[TBL] [Abstract][Full Text] [Related]
15. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
Malkowicz SB; McKenna WG; Vaughn DJ; Wan XS; Propert KJ; Rockwell K; Marks SH; Wein AJ; Kennedy AR
Prostate; 2001 Jun; 48(1):16-28. PubMed ID: 11391683
[TBL] [Abstract][Full Text] [Related]
16. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
Armstrong WB; Taylor TH; Kennedy AR; Melrose RJ; Messadi DV; Gu M; Le AD; Perloff M; Civantos F; Goodwin WJ; Wirth LJ; Kerr AR; Meyskens FL
Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
[TBL] [Abstract][Full Text] [Related]
17. Prevention of carcinogenesis by protease inhibitors.
Kennedy AR
Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells.
Wan XS; Hamilton TC; Ware JH; Donahue JJ; Kennedy AR
Nutr Cancer; 1998; 31(1):8-17. PubMed ID: 9682243
[TBL] [Abstract][Full Text] [Related]
19. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor.
Billings PC; Habres JM; Liao DC; Tuttle SW
Cancer Res; 1991 Oct; 51(20):5539-43. PubMed ID: 1913672
[TBL] [Abstract][Full Text] [Related]
20. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
Yavelow J; Caggana M; Beck KA
Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
